Pyridine-containing antitumor agents: structure-oriented medicinal chemistry, structure–activity relationships, and ADMET liabilities Authors: Wei Zhao, Beibei Bie, Juning Wang, Xueying Liu, Huanle Fang, Rui Niu Published: 2026 ABSTRACT AbstractPyridine is a common nitrogen-containing heteroaromatic motif in antitumor medicinal chemistry, but its design value is highly context dependent. Here, we synthesize structure-oriented medicinal chemistry principles that govern the use of pyridine-related motifs in antitumor drug design. We discuss pyridine-containing antitumor agents with emphasis on target recognition, scaffold organization, structure–activity relationship (SAR), drug metabolism and pharmacokinetics (DMPK), and absorption, distribution, metabolism, excretion, and toxicity (ADMET) liabilities. Representative approved drugs, antibody–drug conjugate (ADC) payloads, targeted degraders, and polypyridyl metal complexes are used to illustrate how pyridine-related motifs can support binding, property tuning, and modality adaptation. By grouping representative compounds according to the medicinal chemistry function of their pyridine-related motifs, this review provides a practical framework for future scaffold design. Overall, pyridine should not be viewed as a universally beneficial privileged scaffold; it is better treated as a context-dependent design module that requires validation through integrated structural, SAR, ADMET, and translational evidence. Keywords: Pyridine, Antitumor agents, Medicinal chemistry, Structure–activity relationship, ADMET, Targeted protein degradation Introduction Cancer continues to be a major global health burden despite substantial advances in targeted therapy, immunotherapy, antibody–drug conjugates (ADCs), and precision oncology. Recent global statistics show high incidence and mortality across major tumor types, while tumor heterogeneity, acquired resistance, dose-limiting toxicity, insufficient exposure in sanctuary sites, and unequal access to effective therapies remain important clinical challenges [1, 2]. These issues continue to drive the discovery of antitumor agents with improved selectivity, safety, pharmacokinetic behavior, and durability of response. Nitrogen-containing heterocycles occupy a central position in small-molecule drug discovery. Recent analyses of approved pharmaceuticals show that azaheterocycles remain highly represented in modern drugs, and pyridine is among the recurrent heteroaromatic motifs in approved drug structures [3, 4]. These analyses support the relevance of nitrogen heterocycles, including pyridine motifs, to oncology-oriented drug design, scaffold diversification, and property tuning. The appeal of pyridine lies in its chemical simplicity and functional versatility. A pyridine ring can act as a hydrogen-bond acceptor, serve as a phenyl bioisostere, alter molecular dipole, tune lipophilicity, and influence the physicochemical profile of drug-like molecules [5, 6]. In selected molecular contexts, pyridine nitrogen atoms may coordinate heme centers, as illustrated by cytochrome P450 17A1 (CYP17A1) inhibition [7]. Pyridine and polypyridyl motifs may also support metal–ligand interactions and metallodrug design [8, 9], including light-responsive Ru(II) polypyridyl systems [10]. These properties can improve target recognition, solubility, or scaffold geometry, although their consequences are not universally favorable. Increased polarity may reduce passive permeability or alter exposure, whereas susceptible azaheteroaromatic systems may introduce aldehyde oxidase (AO)-mediated metabolic liability [6, 11, 12]. Therefore, pyridine incorporation should be treated as a defined design hypothesis rather than a routine heteroaryl substitution. In oncology drug discovery, pyridine-containing chemotypes appear across several therapeutic classes, including ATP-site kinase inhibitors, allosteric kinase inhibitors, endocrine modulators, antimetabolite regimen components, histone deacetylase (HDAC) inhibitors, ADC payloads and linkers, targeted protein degraders, and metal complexes. Representative clinical examples include crizotinib and lorlatinib [13, 14], abiraterone and asciminib [15, 16], and chidamide and gimeracil [17, 18]. Across these molecules, pyridine is not a single pharmacophore with a fixed function. Depending on its position, substitution pattern, electronic properties, and three-dimensional environment, it may anchor a ligand in a kinase ATP-binding site, coordinate heme iron, organize scaffold geometry, tune polarity, provide a linker exit vector, influence oral exposure, or support photophysical tuning in metal complexes. The purpose of this review is to clarify the medicinal chemistry logic underlying pyridine-containing antitumor agents. The central thesis is that pyridine is best understood as a context-dependent design module. Its value is determined by four interrelated dimensions: target recognition, scaffold optimization, ADMET tuning, and therapeutic modality compatibility. These four dimensions provide the conceptual framework of this review, as summarized in Fig. 1. Structure-oriented framework of pyridine-containing antitumor agent design Scope and literature selection For this review, pyridine-containing antitumor agents are defined as compounds in which a pyridine, pyridyl, fused pyridine, pyridinone, or polypyridyl motif contributes meaningfully to antitumor activity, target recognition, molecular conformation, physicochemical properties, metabolic behavior, or therapeutic platform design. Compounds in which pyridine is only an incidental structural fragment without a defined or reasonably inferred medicinal chemistry role are not emphasized. This article is a narrative medicinal chemistry review rather than a systematic review. Literature was selected to highlight approved drugs, structurally characterized inhibitors, representative SAR studies, clinically relevant emerging modalities, and investigations addressing physicochemical or DMPK properties of pyridine-containing antitumor agents. PubMed, Web of Science, Scopus, ClinicalTrials.gov, official regulatory sources, and journal databases were consulted. Publications from 2021 onward were prioritized where possible, while earlier landmark studies were retained when they reported approved drugs, key structural evidence, seminal SAR principles, or established clinical validation. Search terms included “pyridine”, “pyridinone”, “pyridyl”, “anticancer”, “antitumor”, “kinase inhibitor”, “PIM kinase”, “PIM1”, “PIM2”, “PIM3”, “HDAC inhibitor”, “targeted protein degradation”, “ADC payload”, “metallodrug”, “aldehyde oxidase”, and “hERG”. Priority was given to approved drugs, structurally characterized compounds, recent medicinal chemistry studies, and reviews directly addressing SAR, DMPK, ADMET, or modality-oriented design. The final reference set was refined by excluding reports in which the pyridine motif was merely incidental and by retaining earlier landmark studies when they provided approved-drug validation, structural evidence, or foundational SAR principles. Matched molecular pair analysis and bioisosteric replacement literature were also considered when interpreting pyridine-driven property changes [19, 20]. Because this review was not conducted according to PRISMA guidelines, it does not claim exhaustive database screening, meta-analysis, or quantitative evidence synthesis. No formal quantitative screening or risk-of-bias assessment was performed because the purpose of this article was to synthesize medicinal chemistry principles rather than to conduct a systematic review. Instead, it integrates medicinal chemistry concepts, structure-based insights, SAR trends, DMPK liabilities, and translational lessons that may guide future design of pyridine-containing antitumor agents. Functional classification of pyridine-containing antitumor agents Pyridine-containing antitumor agents can be classified according to the functional contribution of the pyridine-related motif rather than only by therapeutic class. This function-oriented classification separates direct binding-site recognition, scaffold organization, physicochemical modulation, metal coordination, and platform-oriented applications. The categories overlap, and the same pyridine ring may contribute to more than one design objective. The first category involves direct recognition within a binding site. Pyridine nitrogen atoms or aminopyridine donor–acceptor patterns may participate in hydrogen bonding, while pyridyl groups can also support heme or metal-center engagement in selected targets [7, 13, 14]. The second category involves scaffold organization. Fused pyridine systems can impose rigid geometry and orient substituents within kinase-relevant scaffolds [21, 22]. Pyridine-carboxamide motifs can further help position adjacent pharmacophores toward hinge-proximal regions and hydrophobic back pockets in type II kinase inhibitor design [23, 24]. Broader analyses of approved kinase inhibitors support the clinical relevance of such scaffold-level optimization [25]. The third category involves physicochemical and metabolic modulation. Phenyl-to-pyridine replacement can alter dipole orientation, lipophilicity, hydrogen-bond acceptor count, solubility, permeability, and metabolic pathways, but these effects remain highly scaffold-dependent [5, 6, 11, 12]. More broadly, matched molecular pair analysis and bioisostere-guided design provide useful frameworks for distinguishing productive heteroaryl replacement from changes that merely shift physicochemical liabilities [19, 20, 26]. The fourth category involves coordination chemistry. Pyridine and polypyridyl ligands may tune metal–ligand interactions and coordination geometry [8, 9]. Light-responsive Ru(II) polypyridyl systems further illustrate how such ligands can modulate redox behavior, light absorption, reactive oxygen species generation, and metal-complex stability [10]. The fifth category involves platform adaptation. Pyridine-containing inhibitors may be incorporated into targeted degraders when target engagement and protein-degradation principles are preserved [27, 28]. Ternary-complex behavior and proteolysis-targeting chimera (PROTAC) design constraints further determine whether such warheads remain productive [29, 30]. Pyridine-containing topoisomerase I payloads can support ADC design [31, 32], whereas pyridazinedione-based chemistry can support site-selective antibody conjugation [33]. Approved pyridine-containing antitumor agents and clinically established regimen components Approved pyridine-containing antitumor agents provide the strongest clinical validation for the medicinal chemistry roles summarized above (Table 1). Rather than serving as a simple inventory, these examples show how pyridine-related motifs can be translated into kinase inhibition, endocrine modulation, allosteric inhibition, epigenetic therapy, antimetabolite regimens, antiangiogenic therapy, and type II multikinase inhibition. Gimeracil-containing fluoropyrimidine therapy further illustrates the value of pyridinone-mediated enzyme inhibition in a clinical regimen [34]. Table 1Representative approved pyridine-containing antitumor agents and clinically established regimen componentsDrugPyridine-related motifFunctional contributionPrimary target(s)Main indication(s)Key medicinal chemistry lessoncrizotinib2-AminopyridineBidentate hinge recognitionALK, ROS1, METALK- or ROS1-positive NSCLCCompact donor–acceptor hinge pharmacophorelorlatinibMacrocyclic 2-aminopyridineHinge binding and conformational preorganizationALK, ROS1ALK-positive NSCLCMacrocyclization improves mutation coverage and CNS exposureabiraterone3-PyridylHeme iron coordinationCYP17A1Prostate cancerPyridine as metalloenzyme-binding groupsorafenibPyridine-2-carboxamideType II multikinase scaffoldRAF, VEGFR, PDGFR, KITHCC, RCC, DTCBack-pocket kinase bindingregorafenibPyridine-2-carboxamideType II multikinase scaffoldVEGFR, PDGFR, RAF, KITCRC, GIST, HCCElectronic changes alter potency/toxicityaxitinibPyridinyl motifVEGFR recognition/property tuningVEGFR1–3RCCSelectivity and polarity tuningasciminibPyridine-containing biarylAllosteric myristoyl-pocket engagementBCR-ABL1Ph-positive CMLAllosteric inhibitionpalbociclibPyrido[2,3-d]pyrimidineRigid bicyclic scaffoldCDK4/6HR-positive/HER2-negative breast cancerProductive scaffold geometrychidamidePyridin-3-ylacrylamideHDAC surface-recognition capHDACsPTCL; breast cancerCap-group recognitiongimeracil5-Chloro-4-hydroxy-2-pyridinoneDPD inhibition in S-1 regimenDPDFluoropyrimidine componentUracil-like enzyme recognitionNote: Functional annotations are based on structural, biochemical, pharmacological, or clinical evidence discussed in the corresponding textAbbreviations: ALK anaplastic lymphoma kinase, CDK cyclin-dependent kinase, CML chronic myeloid leukemia, CRC colorectal cancer, CYP17A1 cytochrome P450 family 17 subfamily A member 1, DPD dihydropyrimidine dehydrogenase, DTC differentiated thyroid cancer, GIST gastrointestinal stromal tumor, HCC hepatocellular carcinoma, HER2 human epidermal growth factor receptor 2, HR hormone receptor, KIT KIT proto-oncogene receptor tyrosine kinase, MET mesenchymal-epithelial transition factor, NSCLC non-small-cell lung cancer, PDGFR platelet-derived growth factor receptor, Ph Philadelphia chromosome, PTCL peripheral T-cell lymphoma, RAF rapidly accelerated fibrosarcoma kinase, RCC renal cell carcinoma, ROS1 ROS proto-oncogene 1 receptor tyrosine kinase, VEGFR vascular endothelial growth factor receptor Representative approved pyridine-containing antitumor agents and clinically established regimen components Note: Functional annotations are based on structural, biochemical, pharmacological, or clinical evidence discussed in the corresponding text Abbreviations: ALK anaplastic lymphoma kinase, CDK cyclin-dependent kinase, CML chronic myeloid leukemia, CRC colorectal cancer, CYP17A1 cytochrome P450 family 17 subfamily A member 1, DPD dihydropyrimidine dehydrogenase, DTC differentiated thyroid cancer, GIST gastrointestinal stromal tumor, HCC hepatocellular carcinoma, HER2 human epidermal growth factor receptor 2, HR hormone receptor, KIT KIT proto-oncogene receptor tyrosine kinase, MET mesenchymal-epithelial transition factor, NSCLC non-small-cell lung cancer, PDGFR platelet-derived growth factor receptor, Ph Philadelphia chromosome, PTCL peripheral T-cell lymphoma, RAF rapidly accelerated fibrosarcoma kinase, RCC renal cell carcinoma, ROS1 ROS proto-oncogene 1 receptor tyrosine kinase, VEGFR vascular endothelial growth factor receptor Crizotinib and lorlatinib represent clinically validated anaplastic lymphoma kinase (ALK)- and ROS proto-oncogene 1 receptor tyrosine kinase (ROS1)-directed inhibitors in which 2-aminopyridine-based recognition is embedded in distinct molecular frameworks [13, 14, 35]. Their clinical use also illustrates a key translational constraint of kinase-directed scaffolds: resistance may emerge through kinase-domain mutations and compound mutations [36, 37], while additional preclinical and functional studies emphasize sequential treatment and bypass signaling challenges [38, 39]. Abiraterone illustrates heme coordination in endocrine therapy [7, 15]. Sorafenib and regorafenib exemplify pyridine-carboxamide-containing type II multikinase inhibition [23, 24]. Axitinib illustrates VEGFR-oriented property tuning [40], whereas asciminib represents allosteric BCR-ABL1 inhibition [16, 41]. Palbociclib, chidamide, and gimeracil further show that pyridine-related motifs can support rigid scaffold organization, HDAC surface recognition, or pyridinone-mediated dihydropyrimidine dehydrogenase (DPD) inhibition [17, 21, 34]. These agents are included because their pyridine- or pyridinone-related fragments have a defined medicinal chemistry function; compounds in which pyridine is merely incidental fall outside the core scope of this review. Representative structures and pyridine-related functional annotations are shown in Fig. 2. Representative pyridine-containing antitumor agents and clinically established regimen components Target-directed design principles Building on the approved examples in Approved pyridine-containing antitumor agents and clinically established regimen components section, target-directed pyridine design should be interpreted as a set of transferable medicinal chemistry principles rather than a repetition of individual drug histories. In ATP-competitive kinase inhibitors, aminopyridine motifs are most valuable when hinge geometry supports a compact donor–acceptor arrangement, and macrocyclization can further improve conformational preorganization, mutation coverage, and central nervous system (CNS) exposure [14, 35, 37]. For type II kinase inhibition, pyridine-carboxamide motifs can help bridge hinge-proximal regions and hydrophobic back pockets associated with inactive kinase conformations [23, 24]. Approved kinase inhibitor analyses further support the clinical relevance of this binding mode and scaffold class [25]. This strategy can support controlled polypharmacology, but small changes in pyridine substitution, amide orientation, or linker geometry may shift kinome selectivity, exposure, and toxicity risk [24, 25]. The broader relevance of pyridine and pyrimidine derivatives as anticancer scaffolds has also been summarized in a general medicinal chemistry review [42]. Recent and updated literature on proviral integration site for Moloney murine leukemia virus kinases, namely PIM1, PIM2, and PIM3, further extends the kinase-oriented relevance of nitrogen-containing heteroaromatic scaffolds in antitumor medicinal chemistry. PIM kinases are constitutively active serine/threonine kinases involved in tumor-cell survival, proliferation, metabolic adaptation, drug resistance, and immune-evasion-related signaling. Unlike many receptor tyrosine kinases, PIM kinases do not require activation-loop phosphorylation, which makes ATP-site recognition, isoform selectivity, resistance-associated signaling, and whole-molecule ADMET optimization particularly important for inhibitor design. PIM447/LGH447 is particularly relevant to this review because it contains pyridinyl and picolinamide motifs and was developed as a potent and selective PIM1/2/3 inhibitor for hematological malignancies. Together with other representative pan-PIM inhibitors such as AZD1208 and updated PIM3-focused cancer literature, these examples support the broader conclusion that pyridine-containing motifs should be evaluated as context-dependent design modules rather than universally privileged fragments [43–45]. In HDAC inhibitor design, pyridine-containing cap or linker regions should be optimized independently from the zinc-binding group. Recent pyridine-based benzamide studies show that pyridine-containing cap or linker regions can be used to tune isoform selectivity, physicochemical properties, and antitumor activity [46]. Reviews on HDAC-related combination strategies [47], benzamide HDAC inhibitors [48], o-aminobenzamide-based HDAC scaffolds [49], and representative HDAC inhibitors [50] emphasize that cap-group recognition, zinc-binding chemistry, target combination strategy, and whole-molecule pharmacokinetic behavior should be considered as separable but interdependent design variables. For topoisomerase and tubulin-directed agents, pyridine-related fragments should be evaluated in relation to the complete molecular architecture. Exatecan-derived topoisomerase I payloads require assessment at the antibody–linker–payload level [31, 32], whereas diarylpyridine colchicine-site inhibitors and recent colchicine-site inhibitor studies require optimization of potency, multidrug-resistance activity, vascular-disrupting potential, and safety window [51–53]. Non-kinase examples reinforce the same design logic. Pyridyl heme coordination and pyridinone-mediated enzyme inhibition are useful only when the electronic, tautomeric, and three-dimensional features of the motif match the biological target and pharmacokinetic setting [7, 15, 18, 34]. Pyridinone derivatives: distinct binding and electronic logic Pyridinones should not be regarded as simple analogues of pyridines. Conversion of a pyridine ring into a 2-pyridinone or 4-pyridinone changes electron distribution, hydrogen-bonding topology, tautomeric behavior, basicity, metal-binding ability, and permeability [54]. Through lactam–lactim tautomerism, pyridinones can emulate amide-, uracil-, or nucleobase-like hydrogen-bonding patterns that are not readily accessible to unsubstituted pyridine rings. Several medicinal chemistry consequences arise from pyridine-to-pyridinone switching. The position of the carbonyl group determines the spatial arrangement of hydrogen-bond donors and acceptors, which can directly influence target recognition and selectivity. N1 substitution provides a vector for extension into hydrophobic or solvent-exposed regions. Electron-withdrawing substituents can tune lipophilicity, basicity, and metabolic stability [54]. In antitumor research, gimeracil is a clinically established example of pyridinone-mediated DPD inhibition [18, 34], whereas copper complexes bearing pyridinone-derived ligands illustrate how such scaffolds can support metal binding, DNA interaction, and cytotoxicity [55]. From a design perspective, pyridine-to-pyridinone conversion should be treated as scaffold hopping rather than routine analogue modification. This transformation may strengthen a binding hypothesis, but it can also reduce permeability, alter tautomeric preference, or change metabolic stability. Therefore, pyridinone SAR should be developed independently, with direct comparison against pyridine, phenyl, pyrimidine, and other heteroaryl analogues when possible. Structure–activity relationship and ADMET principles The 2-aminopyridine donor–acceptor motif is an efficient ATP-site anchoring element when the kinase hinge geometry supports bidentate recognition. The pyridine nitrogen typically acts as a hydrogen-bond acceptor, while the exocyclic amino group serves as a hydrogen-bond donor [13, 14]. The 4-position of the 2-aminopyridine ring often projects toward solvent-exposed space, making it a useful exit vector for linker attachment in degrader design when target binding is preserved [27, 28]. However, ternary-complex behavior and degrader-specific design constraints must also be considered [29, 30]. Phenyl-to-pyridine replacement is widely used to modulate polarity, dipole orientation, ligand efficiency, solubility, and metabolic behavior [5, 6]. Interpreting such replacements through matched molecular pairs can help separate pyridine-specific effects from changes driven by size, shape, or global polarity [19]. The ring nitrogen can reduce lipophilicity and introduce an additional hydrogen-bond acceptor. However, the outcome is highly scaffold-dependent. In some matched molecular pairs, pyridine incorporation improves solubility or target engagement; in others, it reduces passive permeability, introduces AO liability, changes efflux behavior, or alters off-target profiles [6, 11, 12]. Pyridine carboxamide motifs are useful in type II multikinase inhibitor design because they can combine hinge-proximal recognition with occupation of hydrophobic back pockets [23, 24]. Approved kinase inhibitor analyses further support the relevance of these type II binding features [25]. This arrangement can support controlled polypharmacology, but it can also create broad kinome activity and dose-limiting toxicity. Pyridine-to-pyridinone switching changes hydrogen-bonding pattern, tautomeric preference, electronic distribution, metal-binding behavior, and pKa [54]. This strategy can be useful when a program seeks uracil-like recognition, altered donor–acceptor topology, or metal-binding behavior. However, altered tautomer populations may weaken target affinity, change hydrogen-bonding geometry, or create permeability and metabolic-stability uncertainty. Aromatic nitrogen-containing heterocycles can undergo N-oxidation mediated by flavin-containing monooxygenases or related oxidative systems [56]. AO-mediated carbon oxidation in susceptible heteroaromatic systems is another important pyridine-associated liability [11, 12, 57]. AO liability can be species-dependent and difficult to predict from microsomal stability alone. Early AO phenotyping, cytosolic stability assays, humanized liver models, and metabolite identification should therefore be incorporated into pyridine scaffold optimization. Recent synthetic approaches to authentic AO metabolite standards may further support metabolite identification and structural confirmation when AO oxidation is suspected [58]. Lipophilic, planar, and basic heteroaromatic scaffolds may inhibit the hERG potassium channel, encoded by the human ether-à-go-go–related gene, creating a potential cardiac safety liability [59, 60]. Structure-based prediction studies further emphasize the importance of early hERG risk profiling [61]. hERG mitigation strategies include lowering cLogP, reducing basicity, increasing three-dimensionality, and redistributing polar surface area. Similarly, pyridine incorporation can improve aqueous solubility but may reduce passive permeability or increase efflux liability [5, 6, 62]. Therefore, pyridine-based optimization should be guided by multiparameter profiling rather than single-property improvement. The major medicinal chemistry strategies and associated liabilities of pyridine-related motifs are summarized in Table 2. Table 2Medicinal chemistry strategies and liabilities of pyridine-related motifsDesign strategyWhen usefulMain benefitMain riskRepresentative examples2-Aminopyridine hinge motifKinase hinge supports bidentate recognitionEfficient ATP-site anchoringMutation-driven resistancecrizotinib, lorlatinibMacrocyclic pyridine-containing scaffoldBioactive conformation can be preorganizedMutation coverage, CNS exposureSynthetic complexity, resistancelorlatinibPhenyl-to-pyridine replacementNeed polarity or dipole tuningSolubility and HBA introductionPermeability loss, AO metabolismPhenyl/pyridyl matched molecular pairsPyridine-2-carboxamide motifType II kinase bindingBack-pocket engagementBroad kinome activitysorafenib, regorafenibPyridine-to-pyridinone switchingNeed uracil-like or altered H-bondingNew donor–acceptor topologyTautomer-driven affinity or permeability issuesgimeracilPyridine metal coordinationHeme or metal-center engagementMetalloenzyme/metal-complex bindingSelectivity and toxicityabiraterone; Ru(II) polypyridyl and pyridine-containing Pt complexesSolvent-exposed pyridyl vectorWarhead conversion to degraderLinker attachmentTernary complex disruptionBCR-ABL1 and selected kinase PROTACsPyridine-containing payload/conjugation strategyADC payload or conjugation designHydrophilicity, linker compatibility, and conjugation controlADC-specific payload/linker toxicityExatecan/DXd payloads; pyridazinedione-based conjugationAbbreviations: ADC antibody–drug conjugate, AO aldehyde oxidase, BCR-ABL1 breakpoint cluster region-Abelson tyrosine-protein kinase 1 fusion, CNS central nervous system, DXd deruxtecan payload, HBA hydrogen-bond acceptor, PROTAC proteolysis-targeting chimera Medicinal chemistry strategies and liabilities of pyridine-related motifs Abbreviations: ADC antibody–drug conjugate, AO aldehyde oxidase, BCR-ABL1 breakpoint cluster region-Abelson tyrosine-protein kinase 1 fusion, CNS central nervous system, DXd deruxtecan payload, HBA hydrogen-bond acceptor, PROTAC proteolysis-targeting chimera The major SAR and ADMET decision points associated with pyridine-related motifs are summarized in Fig. 3. SAR and ADMET decision points for pyridine-related motifs Pyridine-related motifs in platform-oriented antitumor design Targeted protein degradation promotes proximity between a target protein and an E3 ubiquitin ligase, resulting in ubiquitination and proteasomal degradation [28, 63]. Pyridine-containing inhibitor scaffolds can be repurposed as target-binding warheads in degrader design when the pyridine-containing pharmacophore retains target recognition and presents a solvent-exposed vector suitable for linker attachment. Ternary-complex behavior and degrader design principles remain central to this strategy [27, 29]. BCR-ABL1-directed degraders illustrate how kinase inhibitor chemotypes can be adapted to targeted degradation platforms [64]. These examples should not be interpreted as evidence that pyridine is a universal PROTAC-enabling motif [65]. Many PROTACs occupy beyond-rule-of-five chemical space and face challenges related to permeability measurement, tissue exposure, and resistance [29, 66]. These constraints make physicochemical-property control, conformational behavior, and oral exposure central considerations rather than late-stage optimization details [67–69]. Pyridine-containing topoisomerase I inhibitor payloads, particularly exatecan-derived DXd payloads used in deruxtecan-based ADCs, have become important in ADC development [31, 32, 70]. The broader ADC field also underscores that payload selection, linker stability, drug-to-antibody ratio, tumor penetration, and resistance mechanisms must be evaluated as an integrated pharmacological system [71–74]. Trastuzumab deruxtecan has demonstrated the clinical relevance of this payload class in HER2-positive and HER2-low breast cancer [32, 75, 76]. In ADCs, payload performance cannot be judged only by free-drug potency. Hydrophilicity, linker compatibility, cleavability, bystander effect, systemic stability, antigen expression, drug-to-antibody ratio, tumor penetration, and resistance mechanisms must be optimized at the complete antibody–linker–payload level [70, 72, 77]. Pyridine and polypyridyl ligands are widely used in metallodrug and phototherapeutic design because they can tune metal–ligand interactions, coordination geometry, redox behavior, light absorption, and reactive oxygen species generation [8–10, 78]. Representative monofunctional platinum, organelle-targeted platinum, and Ru(II) polypyridyl complexes further illustrate anticancer mechanisms involving DNA damage, organelle targeting, supramolecular assembly, or light-controlled cytotoxicity [79–82]. Despite this promise, most pyridine-containing metal complexes remain preclinical or early translational. Taken together, these platform-oriented examples show that pyridine-related motifs should be evaluated at the level of the complete therapeutic modality rather than as isolated fragments. For degraders, ADCs, and metal complexes, linker geometry, molecular size, delivery context, payload release, photophysical behavior, and systemic exposure may determine therapeutic performance as strongly as intrinsic target affinity. Major challenges in pyridine-based antitumor drug design Acquired resistance remains a major limitation of pyridine-containing kinase inhibitors. In ALK-positive NSCLC, compound ALK mutations can reduce the durability of responses to sequential ALK inhibitors [37, 38]. Bypass signaling pathways can also sustain tumor growth despite ALK inhibition [39, 83]. Strategies such as macrocyclization, allosteric inhibition, combination therapy, and targeted degradation may help address selected resistance mechanisms, but they do not remove the need for biomarker-guided patient selection and rational treatment sequencing. Metabolic instability is another recurrent challenge. As discussed in Structure–activity relationship and ADMET principles section, pyridine rings can be susceptible to N-oxidation or AO-mediated oxidation in susceptible heteroaromatic systems [56, 57]. These pathways may reduce oral exposure, shorten half-life, or generate inactive metabolites. Because AO metabolism can be difficult to predict and may differ across species, early identification of AO-sensitive motifs is critical. Safety and developability must also be considered early. Lipophilic, planar, and basic pyridine-containing scaffolds may inhibit hERG, creating a potential cardiac safety liability [59, 60]. Structure-based prediction studies further support early hERG risk assessment [61]. Introducing pyridine in place of phenyl can improve aqueous solubility in some scaffolds, but increased polarity may reduce passive permeability, enhance efflux susceptibility, or limit exposure in privileged sites such as the brain [5, 6, 62]. Finally, pyridine-associated PROTACs, ADC technologies, and metal complexes differ substantially in evidence level. Deruxtecan-related topoisomerase I payloads have reached clinical validation [31, 32, 70]. Next-generation ADC linker technologies are also moving toward more advanced translational development [72, 73, 77]. In contrast, pyridine-containing degrader applications remain largely preclinical or early translational [27, 29, 64], and many pyridine-containing metal complexes also remain at preclinical or early translational stages [79, 80]. Future directions Future development of pyridine-containing kinase inhibitors should integrate structural biology, resistance mutation profiling, macrocyclic design, allosteric targeting, and DMPK optimization. The most successful next-generation compounds will need to combine broad mutation coverage with adequate central nervous system exposure, favorable selectivity, and manageable safety liabilities. Recent reviews of ALK inhibitor resistance and asciminib-based BCR-ABL1 therapy further reinforce the need to connect scaffold design with resistance biology and clinical sequencing [84, 85]. In addition, the PIM kinase literature suggests that future pyridine-containing kinase inhibitor design should not be limited to receptor tyrosine kinases or BCR-ABL1-centered scaffolds, but should also consider serine/threonine kinase families in which ATP-site topology, isoform selectivity, metabolic adaptation, and resistance-associated signaling create distinct medicinal chemistry requirements [45]. Pyridine-containing warheads with solvent-facing exit vectors remain attractive for degrader design, but future programs should move beyond degradation potency as the sole endpoint. Target engagement, ternary-complex formation, degrader resistance, conformational behavior, cellular permeability, and oral absorption should be optimized together rather than sequentially [29, 86, 87]. Pyridine-containing payloads and pyridazinedione-based conjugation chemistry may support more hydrophilic, homogeneous, and structurally defined ADCs [31, 33, 70, 77]. Current ADC development further emphasizes that next-generation designs must address payload resistance, antigen heterogeneity, linker stability, and treatment sequencing [72, 73, 88]. Future studies should clarify how pyridine-related polarity, linker placement, release kinetics, conjugation site, payload resistance, antigen heterogeneity, and bystander activity affect the therapeutic index. Next-generation and dual-payload ADC strategies further suggest that conjugation architecture and payload diversity may be needed to address antigen heterogeneity, payload resistance, and therapeutic-index limitations [89, 90]. Polypyridyl ligands offer a versatile platform for tuning coordination geometry, redox behavior, photophysical properties, and biological targeting [8, 9, 78]. Ru(II) polypyridyl systems further demonstrate the value of light-responsive design [10]. For clinical translation, however, pyridine-containing metal complexes must still overcome tumor-selective delivery, limited light penetration, off-target toxicity, metabolic instability, and pharmacokinetic uncertainty. Practically, future pyridine-containing antitumor programs should incorporate matched molecular pair analysis, early cytosolic metabolism screening, permeability–efflux profiling, hERG counterscreening, and structure-guided exit-vector selection. AI models may help predict how substituents at different pyridine positions affect AO-mediated metabolic stability, permeability, and hERG liability, whereas molecular dynamics simulations may help prioritize pyridine-nitrogen orientation and linker exit vectors in PROTAC or other bifunctional designs. Broader machine-learning workflows in drug discovery can further support multiparameter prioritization, but their outputs remain dependent on data quality and experimental validation [91, 92]. These approaches should be used as decision-support tools rather than replacements for experimental SAR, DMPK, and safety validation. Beyond classical inhibitors and PROTACs, pyridine-containing scaffolds may also be cautiously explored in selected covalent or proximity-inducing designs, provided that a clear pyridine-specific design hypothesis is maintained. These opportunities should be balanced against risks such as excessive polarity, AO susceptibility, nonspecific metal coordination, or disruption of ternary-complex geometry. Finally, for clinically established pyridine-containing kinase inhibitors, scaffold optimization should be linked to biomarker-informed treatment strategies. In this context, circulating tumor DNA analysis may help monitor secondary resistance mutations and support personalized sequential therapy [93]. Conclusions Pyridine has progressed from a classical heteroaromatic pharmacophore to a versatile medicinal chemistry module in antitumor drug design. Across approved drugs and emerging modalities, pyridine-related motifs contribute to target recognition, scaffold organization, ADMET tuning, and platform compatibility. Their value, however, is determined by molecular context rather than by the presence of the pyridine ring alone. Future pyridine-based antitumor drug design should therefore begin with a clear hypothesis, such as introducing a hinge-binding acceptor, modulating polarity, creating a linker exit vector, mitigating metabolic liability, or enabling controlled metal coordination. Each hypothesis should then be validated through comparative SAR, DMPK profiling, safety assessment, and, where relevant, modality-level evaluation. Acknowledgements The authors would like to thank the School of Medicine, Xi’an Peihua University for providing literature access and a supportive research environment. We are also grateful to our colleagues for their valuable discussions and critical reading of the manuscript. Abbreviations antibody–drug conjugate absorption, distribution, metabolism, excretion, and toxicity anaplastic lymphoma kinase aldehyde oxidase breakpoint cluster region-Abelson tyrosine-protein kinase 1 fusion cyclin-dependent kinase chronic myeloid leukemia central nervous system colorectal cancer cytochrome P450 family 17 subfamily A member 1 drug metabolism and pharmacokinetics dihydropyrimidine dehydrogenase differentiated thyroid cancer gastrointestinal stromal tumor hepatocellular carcinoma histone deacetylase human ether-à-go-go–related gene hormone receptor mesenchymal-epithelial transition factor non-small-cell lung cancer Philadelphia chromosome proteolysis-targeting chimera peripheral T-cell lymphoma renal cell carcinoma ROS proto-oncogene 1 receptor tyrosine kinase structure–activity relationship vascular endothelial growth factor receptor Author contributions W.Z. conceived and supervised the review. B.B. and J.W. performed the literature search and drafted the initial manuscript. X.L. and H.F. contributed to the SAR, DMPK, and emerging modality analysis. R.N. organized the manuscript, designed the figures and tables, and revised the manuscript. All authors reviewed and approved the final manuscript. Funding This research was supported by the Natural Science Special Research Program of the Education Department of Shaanxi Province (Program No. 25JK0596). Data availability No datasets were generated or analysed during the current study. Declarations Use of generative AI and AI-assisted technologies During the preparation of this manuscript, AI-assisted tools were used only for language editing, readability improvement, and formatting support. The authors independently verified the scientific content, reference selection, interpretation, and conclusions, and take full responsibility for the final manuscript. Conflict of interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.